Announcement

Collapse
No announcement yet.

J Infect Dis . Plasma from recovered COVID-19 subjects inhibits spike protein binding to ACE2 in a microsphere-based inhibition assay

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • J Infect Dis . Plasma from recovered COVID-19 subjects inhibits spike protein binding to ACE2 in a microsphere-based inhibition assay


    J Infect Dis


    . 2020 Aug 15;jiaa508.
    doi: 10.1093/infdis/jiaa508. Online ahead of print.
    Plasma from recovered COVID-19 subjects inhibits spike protein binding to ACE2 in a microsphere-based inhibition assay


    Edward P Gniffke 1 , Whitney E Harrington 2 3 , Nicholas Dambrauskas 2 , Yonghou Jiang 2 , Olesya Trakhimets 2 , Vladimir Vigdorovich 2 , Lisa Frenkel 2 3 , D Noah Sather 2 3 , Stephen E P Smith 1 3 4



    Affiliations

    Abstract

    We present a microsphere-based flow cytometry assay that quantifies the ability of plasma to inhibit the binding of spike protein to angiotensin converting enzyme 2 (ACE2). Plasma from 22 subjects who recovered from mild Coronavirus disease 2019 (COVID-19) and expressed anti-spike-trimer IgGs inhibited ACE2-spike binding to a greater degree than controls. The degree of inhibition correlated with anti-spike IgG levels, neutralizing titers in a pseudotyped lentiviral assay, and the presence of fever during illness. This inhibition assay may be broadly useful to quantify the functional antibody response of recovered COVID-19 patients or vaccine recipients in a cell-free assay system.

    Keywords: ACE2; COVID-19; SARS-COV-2; Spike; binding inhibition; neutralization; serology.

Working...
X